全新UICC食管癌TNM分期

2015-02-04 smoon 医学论坛网

最新国际食管癌TNM分期(UICC/AJCC 2009第7版) 一、食管癌的分段 与以往不同,新版食管癌TNM标准对食管癌的原发部位以肿块上缘所在的食管位置决定,以上切牙到肿块上缘的距离来表示具体位置: 颈段食管:上接下咽,向下至胸骨切迹平面的胸廓入口,内镜检查距门齿15厘米至<20厘米。 胸上段食管:上自胸廓入口,下至奇静脉弓下缘水平,内镜检查距门齿20厘米至<25厘米。

更新见:UICC/AJCC 2017年第八版食管癌 TNM 分期标准

最新国际食管癌TNM分期(UICC/AJCC 2009第7版)

一、食管癌的分段

与以往不同,新版食管癌TNM标准对食管癌的原发部位以肿块上缘所在的食管位置决定,以上切牙到肿块上缘的距离来表示具体位置:

颈段食管:上接下咽,向下至胸骨切迹平面的胸廓入口,内镜检查距门齿15厘米至<20厘米。

胸上段食管:上自胸廓入口,下至奇静脉弓下缘水平,内镜检查距门齿20厘米至<25厘米。

胸中段食管:上自奇静脉弓下缘,下至下肺静脉水平,内镜检查距门齿25厘米至<30厘米。

胸下段食管:上自下肺静脉水平,向下终于胃,内镜检查距门齿30厘米至<40厘米。

食管胃交界(EGJ)癌:EGJ上5厘米的食管远端与EGJ以下5厘米的胃近端是一个充满争议的部位,新版食管癌TNM分期与胃癌TNM分期内容协调一致,明确规定:凡肿瘤位于1)食管下段;2)侵犯EGJ;均按食管腺癌TNM分期;3)胃近端5厘米内发生的腺癌未侵犯EGJ者可称为贲门癌,连同胃其它部位发生的肿瘤,按胃癌的TNM标准分期。

二、第7版食管癌TNM定义

1、原发肿瘤(Primary Tumor,T)

Tx:原发肿瘤不能确定;

T0:无原发肿瘤证据;

Tis:重度不典型增生;

T1:肿瘤侵犯粘膜固有层、粘膜肌层、或粘膜下层;

T1a:肿瘤侵犯粘膜固有层或粘膜肌层;

T1b:肿瘤侵犯粘膜下层;

T2:肿瘤侵犯食管肌层;

T3:肿瘤侵犯食管纤维膜;

T4:肿瘤侵犯食管周围结构;

T4a:肿瘤侵犯胸膜、心包或膈肌(可手术切除);

T4b:肿瘤侵犯其他邻近结构如主动脉、椎体、气管等(不能手术切除)。

2、区域淋巴结(Regional Lymph Nodes,N)

Nx:区域淋巴结转移不能确定;

N0:无区域淋巴结转移;

N1:1-2枚区域淋巴结转移;

N2:3-6枚区域淋巴结转移;

N3:≥7枚区域淋巴结转移。

注:必须将转移淋巴结数目与清扫淋巴结总数一并记录

3、远处转移(Distant Metastasis,M)

M0:无远方转移;

M1:有远方转移。

4、肿瘤分化程度(Histologic Grade,G)

Gx:分化程度不能确定----按G1分期;

G1:高分化癌;

G2:中分化癌;

G3:低分化癌;

G4:未分化癌----按G3分期。

三、 第7版食管癌TNM分期

1. 鳞状细胞癌(包括其他非腺癌类型)

分期

T

N

M

G

部位*

0

is (HGD)

0

0

1,X

Any

IA

1

0

0

1,X

Any

IB

1

0

0

2-3

Any

 

2-3

0

0

1,X

下段,X

IIA

2-3

0

0

1,X

中、上段

 

2-3

0

0

2-3

下段,X

IIB

2-3

0

0

2-3

中、上段

 

1-2

1

0

Any

Any

IIIA

1-2

2

0

Any

Any

 

3

1

0

Any

Any

 

4a

0

0

Any

Any

IIIB

3

2

0

Any

Any

IIIC

4a

1-2

0

Any

Any

 

4b

Any

0

Any

Any

 

Any

3

0

Any

Any

IV

Any

Any

1

Any

Any

 *:肿瘤部位按肿瘤上缘在食管的位置界定,X指未记载肿瘤部位。

2. 第7版食管癌TNM分期:腺癌

分期

T

N

M

G

0

is (HGD)

0

0

1,X

IA

1

0

0

1-2,X

IB

1

0

0

3

 

2

0

0

1-2,X

IIA

2

0

0

3

IIB

3

0

0

Any

 

1-2

1

0

Any

IIIA

1-2

2

0

Any

 

3

1

0

Any

 

4a

0

0

Any

IIIB

3

2

0

Any

IIIC

4a

1-2

0

Any

 

4b

Any

0

Any

 

Any

3

0

Any

IV

Any

Any

1

Any

四、食管癌的区域淋巴结名称与编码

编码

名称

部位描述

1

锁骨上淋巴结

位于胸骨上切迹与锁骨上

2R

右上气管旁淋巴结

位于气管与无名动脉根部交角与肺尖之间

2L

左上气管旁淋巴结

位于主动脉弓顶与肺尖之间

3P

后纵隔淋巴结

位于气管分叉之上,也称上段食管旁淋巴结

4R

右下气管旁淋巴结

位于气管与无名动脉根部交角与奇静脉头端之间

4L

左下气管旁淋巴结

位于主动脉弓顶与隆突之间

5

主肺动脉窗淋巴结

位于主动脉弓下、主动脉旁及动脉导管侧面

6

前纵隔淋巴结

位于升主动脉和无名动脉前方

7

隆突下淋巴结

位于气管分叉的根部

8M

中段食管旁淋巴结

位于气管隆突至下肺静脉根部之间

8L

下段食管旁淋巴结

位于下肺静脉根部与食管胃交界之间

9

下肺韧带淋巴结

位于下肺韧带内

10R

右气管支气管淋巴结

位于奇静脉头端与右上叶支气管起始部之间

10L

左气管支气管淋巴结

位于隆突与左上叶支气管起始部之间

15

膈肌淋巴结

位于膈肌膨隆面与膈脚之间(膈上)

16

贲门周围淋巴结

位于胃食管交界周围的淋巴结(膈下)

17

胃左淋巴结

位于胃左动脉走行区

18

肝总淋巴结

位于肝总动脉走行区

19

脾淋巴结

位于脾动脉走行区

20

腹腔淋巴结

位于腹腔动脉周围

注:11-肺叶间淋巴结,12-肺叶淋巴结;13-肺段淋巴结;14-肺次段淋巴结不属于食管癌引流淋巴结,本表未列出。

相关阅读

NEJM:食管腺癌临床诊疗综述 

2016 ESMO临床实践指南:食管癌的诊断,治疗及随访

重磅推荐:下载梅斯医学APP,可以尽情下载指南、共识了!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1952218, encodeId=77da19522184c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Jul 07 17:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989310, encodeId=07e7198931066, content=<a href='/topic/show?id=e6c518102aa' target=_blank style='color:#2F92EE;'>#UICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18102, encryptionId=e6c518102aa, topicName=UICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 30 15:12:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376664, encodeId=f79713e6664f5, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437092, encodeId=7986143e092a4, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461997, encodeId=9052146199e01, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-07-07 Eleven11
  2. [GetPortalCommentsPageByObjectIdResponse(id=1952218, encodeId=77da19522184c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Jul 07 17:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989310, encodeId=07e7198931066, content=<a href='/topic/show?id=e6c518102aa' target=_blank style='color:#2F92EE;'>#UICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18102, encryptionId=e6c518102aa, topicName=UICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 30 15:12:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376664, encodeId=f79713e6664f5, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437092, encodeId=7986143e092a4, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461997, encodeId=9052146199e01, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-12-30 mgqwxj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1952218, encodeId=77da19522184c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Jul 07 17:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989310, encodeId=07e7198931066, content=<a href='/topic/show?id=e6c518102aa' target=_blank style='color:#2F92EE;'>#UICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18102, encryptionId=e6c518102aa, topicName=UICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 30 15:12:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376664, encodeId=f79713e6664f5, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437092, encodeId=7986143e092a4, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461997, encodeId=9052146199e01, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1952218, encodeId=77da19522184c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Jul 07 17:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989310, encodeId=07e7198931066, content=<a href='/topic/show?id=e6c518102aa' target=_blank style='color:#2F92EE;'>#UICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18102, encryptionId=e6c518102aa, topicName=UICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 30 15:12:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376664, encodeId=f79713e6664f5, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437092, encodeId=7986143e092a4, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461997, encodeId=9052146199e01, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-02-06 zhouqu_8
  5. [GetPortalCommentsPageByObjectIdResponse(id=1952218, encodeId=77da19522184c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Tue Jul 07 17:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989310, encodeId=07e7198931066, content=<a href='/topic/show?id=e6c518102aa' target=_blank style='color:#2F92EE;'>#UICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18102, encryptionId=e6c518102aa, topicName=UICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 30 15:12:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376664, encodeId=f79713e6664f5, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437092, encodeId=7986143e092a4, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461997, encodeId=9052146199e01, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-02-06 docwu2019

相关资讯

CSCO 2014:食管癌的放疗进展

肿瘤放射治疗论坛地点:2楼2号会议室时间:9月20日15:45~16:10         报告者:上海交通大学附属胸科医院  傅小龙 食管鳞癌初次治疗的总体策略制定主要依赖于患者一般情况、原发病灶所在部位以及治疗前的临床分期。其中最主要参考指标为临床分期。近年来,一些新的手术方式用于早期食管癌的治疗

NEJM:食管腺癌临床诊疗综述

在北美和欧洲食管腺癌是最主要的食管癌类型。胃食管返流性疾病(GERD)和肥胖是主要危险因素。目前已经知道的癌前损害是Barrett食管,通过内镜检查发现,发现后按照癌前损害进行治疗和监控。亚洲、非洲、南美和北美的黑人食管鳞癌是食管癌主要类型。酒精和烟草是主要危险因素,食管鳞状异型增生是主要癌前损害。过去的10年里,尽管食管癌5年生存率仍然很差,但已有改善,早期和局部进展期食管癌病人长期生存可能

Int J Radiat Oncol Biol Phys:术前放化疗结合帕尼单抗治疗可切除食管癌:2期临床试验

目的:术前放化疗治疗(CRT)已成为可切除食管癌患者的标准治疗策略。该多中心2期临床研究旨在研究添加表皮生长因子受体(EGFR)抑制剂—帕尼单抗对于接受术前放化疗治疗(卡铂、紫杉醇和放射治疗)的可切除食管癌患者的功效。方法:具有可切除 cT1N1M0 或者 cT2-3N0 到 -2M0 肿瘤的患者在第1、15和29天接受含帕尼单抗(6 mg/kg)的术前放化疗治疗,每周给药卡铂(曲线下面积[AUC

ASCO GI 2015 :MIRO研究:可切除食管癌行混合微创食管切除术有短期获益

MIRO研究:食管癌患者混合微创和开放性食管切除术比较(摘要号:5) 报告者:Christophe Mariette 报告时间:旧金山时间1月15日,2:00 pm~3:30 pm 研究背景:外科手术被认为是可切除食管癌的唯一治疗选择。术后并发症,特别是肺部并发症,仍然是引起诸多关注的焦点,一半以上行开放性食管切除术(OO)的患者出现并发症。本研究对混合微创食管切除术(HMIO)与OO进行比

吉非替尼靶向疗法或可提高食管癌患者的生存期

近日,在国家癌症研究所癌症(NCRI)会议上,来自阿伯丁大学的研究人员通过研究表示,一种用于治疗肺癌的最新药物可使得特殊食管癌的病人生存期明显延长。在高达六分之一的食管癌患者机体的肿瘤细胞中都能够发现EGFR的复制品,而患者往往通过服用药物吉非替尼来靶向作用该“错误”,进而可以将患者寿命延长至6个月,有时候甚至更长。 抗肿瘤药吉非替尼是一种表皮生长因子受体抑制剂,其已经在日本、美国和澳大利亚

ASCO GI 2015 :TROG 03.01研究:进展期食管癌的姑息性化放疗VS放疗

TROG 03.01研究:进展期食管癌患者放疗或化放疗后吞咽困难缓解和生活质量比较(摘要号:6) 报告者:Michael Penniment 报告时间:旧金山时间1月15日,2:00 pm~3:30 pm 研究背景 放射治疗(RT)可缓解进展期食管癌患者的吞咽困难症状,但尚无Ⅲ期随机试验数据确定其治疗反应、毒性以及姑息性化放疗(CRT)的作用。本研究旨在确立有效、最小毒性的治疗方式以缓解症